Suppr超能文献

慢性肾脏病及肾脏替代治疗的医疗费用:瑞典一项基于人群的队列研究

Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.

作者信息

Eriksson Jonas K, Neovius Martin, Jacobson Stefan H, Elinder Carl-Gustaf, Hylander Britta

机构信息

Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Division of Nephrology, Department of Clinical Sciences, Danderyd University Hospital, Stockholm, Sweden.

出版信息

BMJ Open. 2016 Oct 7;6(10):e012062. doi: 10.1136/bmjopen-2016-012062.

Abstract

OBJECTIVE

To compare healthcare costs in chronic kidney disease (CKD) stage 4 or 5 not on dialysis (estimated glomerular filtration rate <30 mL/min/1.73m), peritoneal dialysis, haemodialysis and in transplanted patients with matched general population comparators.

DESIGN

Population-based cohort study.

SETTING

Swedish national healthcare system.

PARTICIPANTS

Prevalent adult patients with CKD 4 or 5 (n=1046, mean age 68 years), on peritoneal dialysis (n=101; 64 years), on haemodialysis (n=460; 65 years) and with renal transplants (n=825; 52 years) were identified in Stockholm County clinical quality registers for renal disease on 1 January 2010. 5 general population comparators from the same county were matched to each patient by age, sex and index year.

PRIMARY AND SECONDARY OUTCOME MEASURES

Annual healthcare costs in 2009 incurred through inpatient and hospital-based outpatient care and dispensed prescription drugs ascertained from nationwide healthcare registers. Secondary outcomes were annual number of hospital days and outpatient care visits.

RESULTS

Patients on haemodialysis had the highest mean annual cost (€87 600), which was 1.49 (95% CI 1.38 to 1.60) times that observed in peritoneal dialysis (€58 600). The mean annual cost was considerably lower in transplanted patients (€15 500) and in the CKD group (€9600). In patients on haemodialysis, outpatient care costs made up more than two-thirds (€62 500) of the total, while costs related to fluids ($29 900) was the largest cost component in patients on peritoneal dialysis (51%). Compared with their matched general population comparators, the mean annual cost (95% CI) in patients on haemodialysis, peritoneal dialysis, transplanted patients and patients with CKD was 45 (39 to 51), 29 (22 to 37), 11 (10 to 13) and 4.0 (3.6 to 4.5) times higher, respectively.

CONCLUSIONS

The mean annual costs were ∼50% higher in patients on haemodialysis than in those on peritoneal dialysis. Compared with the general population, costs were substantially elevated in all groups, from 4-fold in patients with CKD to 11, 29 and 45 times higher in transplanted patients and patients on peritoneal dialysis and haemodialysis, respectively.

摘要

目的

比较慢性肾脏病(CKD)4期或5期未接受透析治疗(估计肾小球滤过率<30 mL/min/1.73m²)、接受腹膜透析、血液透析的患者以及接受肾移植患者与匹配的普通人群对照者的医疗费用。

设计

基于人群的队列研究。

研究背景

瑞典国家医疗保健系统。

研究对象

2010年1月1日在斯德哥尔摩郡肾脏疾病临床质量登记处确定了患有CKD 4期或5期的成年患者(n = 1046,平均年龄68岁)、接受腹膜透析的患者(n = 101;64岁)、接受血液透析的患者(n = 460;65岁)以及接受肾移植的患者(n = 825;52岁)。从同一郡选取5名普通人群对照者,按照年龄、性别和索引年份与每位患者进行匹配。

主要和次要结局指标

2009年通过住院和基于医院的门诊护理以及从全国医疗保健登记处确定的已配药处方药产生的年度医疗费用。次要结局指标为年度住院天数和门诊就诊次数。

结果

接受血液透析的患者平均年度费用最高(87600欧元),是接受腹膜透析患者(58600欧元)的1.49倍(95%CI 1.38至1.60)。肾移植患者(15500欧元)和CKD组(9600欧元)的平均年度费用则低得多。在接受血液透析的患者中,门诊护理费用占总费用的三分之二以上(62500欧元),而与透析液相关的费用(29900欧元)是接受腹膜透析患者最大的费用组成部分(51%)。与匹配的普通人群对照者相比,接受血液透析、腹膜透析、肾移植患者和CKD患者的平均年度费用(95%CI)分别高出45倍(39至51)、29倍(22至37)、11倍(10至13)和4.0倍(3.6至4.5)。

结论

接受血液透析的患者平均年度费用比接受腹膜透析的患者高约50%。与普通人群相比,所有组的费用均大幅升高,从CKD患者的4倍到肾移植患者、接受腹膜透析和血液透析患者分别高出11倍、29倍和45倍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cede/5073563/90b290e3763a/bmjopen2016012062f01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验